Open-label, phase II, randomised, pilot study to evaluate the safety and efficacy of combination therapy with cetuximab and FOLFOX4 [fluorouracil + folinic acid + oxaliplatin] or FOLFOX4 alone in patients with colorectal cancer and initially non-resectable [hepatic metastases].

Trial Profile

Open-label, phase II, randomised, pilot study to evaluate the safety and efficacy of combination therapy with cetuximab and FOLFOX4 [fluorouracil + folinic acid + oxaliplatin] or FOLFOX4 alone in patients with colorectal cancer and initially non-resectable [hepatic metastases].

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2010 Actual number of patients added to 136 as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Actual initiation date (February 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top